Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs

Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs

Abstract The receptor tyrosine kinase, erythropoietin-producing hepatocellular A4 (EphA4), was recently identified as a molecular target for Alzheimer’s disease (AD). We found that blockade of the interaction of the receptor and its ligands, ephrins, alleviates the disease phenotype in an AD transge...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shuo Gu, Wing-Yu Fu, Amy K. Y. Fu, Estella Pui Sze Tong, Fanny C. F. Ip, Xuhui Huang, Nancy Y. Ip
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2018
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/685192b840f44ae194276059f135d92a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares